---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003332"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:13:38.370259+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Q1 revenue $36.7M (+7% YoY); net loss ($2.9M) vs. income; reaffirms FY22 growth

## Summary
- OA Pain Management revenue $22.7M (+18% YoY); Joint Preservation & Restoration $12.1M (-1%).
- Net loss ($2.9M), ($0.20) per share vs. net income $2.8M ($0.20 diluted) in prior year.
- Adjusted net loss ($1.6M), adjusted gross margin 64% (down YoY) due to supply chain/challenges.
- Cash $90.3M; FY2022 revenue expected toward upper end of low-to-mid single digit growth.
- Appointed Rob Delp as VP U.S. Sales; he previously led Americas for Zimmer Biomet.

## SEC filing metadata
- accession: 0001171843-22-003332
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/0001171843-22-003332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/f8k_050522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003332
- JSON: https://secwatch.observer/filing/0001171843-22-003332.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.